Immunocore Q1 KIMMTRAK net sales $106.7M (+14% YoY); net income $13M vs $5M

Immunocore Holdings plc

2026-Q1 EPS reported $0.25 revenue$106,677,000

KIMMTRAK net sales $106.7M, up 14% YoY; US sales $67.4M (+19.1% YoY), Europe $34.4M.
Net income $13.0M ($0.25 diluted EPS) vs $5.0M ($0.10) in Q1 2025.
Five-year OS data at AACR: KIMMTRAK OS rate 16% vs 8% control in metastatic uveal melanoma (HR 0.67).
Cash and marketable securities $845M; R&D expense $61.1M, SG&A $37.9M.
Phase 3 TEBE-AM (cutaneous melanoma) enrollment expected to complete H1 2026; topline data H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunocore Holdings plc reported the first quarter ended March 31, 2026 results: revenue $106.7 million, net income $13.0 million, EPS $0.25.

Period: the first quarter ended March 31, 2026
Revenue: $106.7 million
Net income: $13.0 million
EPS: $0.25
Result: reported results

Exact text from the filing

2 ef20072537_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunocore Holdings plc filing history →

Source: SEC EDGAR

accession 0001140361-26-019205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.